JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
06/11/23 - 15:44
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
24/10/23 - 15:03
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
27/07/23 - 14:27
Update 2023 Annual Calendar of Corporate Events (104.1 KB)
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
17/07/23 - 7:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
03/07/23 - 11:48
Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
13/06/23 - 15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
07/06/23 - 14:40
Communication of total amount of voting rights (7 June 2023) (141.14 KB)
05/06/23 - 21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
26/05/23 - 7:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
28/04/23 - 12:52
Shareholders' Meeting 2023 (373.48 KB)
27/03/23 - 15:52
Update 2023 Annual Calendar of Corporate Events (483.89 KB)
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
17/03/23 - 22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
28/02/23 - 16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
13/02/23 - 22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
07/02/23 - 12:01
Update 2023 Annual Calendar of Corporate Events (288.3 KB)
22/12/10 - 1:00
2011 Financial calendar (180.28 KB)
20/12/10 - 1:00
Dividend may be distributed in June (445.78 KB)
02/12/10 - 1:00
Comment on position Paper on Vitamin D (53.46 KB)
24/11/10 - 1:00
Change in share capital (46.85 KB)
18/11/10 - 1:00
Financial instruments to employees (48.33 KB)
05/11/10 - 1:00
The BoD approves Q3'10 results (414.16 KB)
02/11/10 - 1:00
Change in share capital (313.61 KB)
08/10/10 - 2:00
2010 Financial calendar update (174.1 KB)
30/09/10 - 2:00
Change in share capital (5.25 KB)
24/09/10 - 2:00
Financial instruments to employees (48.81 KB)
16/09/10 - 2:00
Stock options exercised by key managers (195.67 KB)
02/09/10 - 2:00
Financial instruments to employees (24.27 KB)
06/08/10 - 2:00
The BoD approves H1'10 results (287.11 KB)
07/07/10 - 2:00
Agreement with Meridian Inc. (182.7 KB)
06/07/10 - 2:00
2010 Financial calendar update (174.1 KB)
02/07/10 - 2:00
Financial instruments to employees (24.37 KB)
01/06/10 - 2:00
Acquisition of MUREX product line (102.6 KB)
14/05/10 - 2:00
The BoD approves Q1'10 results (254.05 KB)
27/04/10 - 2:00
Approval of statutory financial statements (182.99 KB)
20/04/10 - 2:00
2010 Financial calendar update (168.23 KB)
14/04/10 - 2:00
Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
09/04/10 - 2:00
China approves new prenatal screening product line on LIAISON (141.08 KB)
02/04/10 - 2:00
Financial instruments to employees (27.79 KB)
22/03/10 - 1:00
The BoD approves FY 2009 results (306.02 KB)
10/03/10 - 1:00
Acquisition of MUREX product line (45.5 KB)
01/03/10 - 1:00
2010 Financial calendar update (192.49 KB)
12/02/10 - 1:00
The BoD approves Q4'09 results (213.8 KB)
18/01/10 - 1:00